International Journal of Breast Cancer最新文献_第10页

Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment. 乳腺癌精准医学：实现真正个性化诊断和治疗的途径。

IF 1.9

International Journal of Breast Cancer Pub Date : 2018-05-09 eCollection Date: 2018-01-01 DOI: 10.1155/2018/4809183

Eleanor E R Harris

引用次数: 0

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. 新辅助帕妥珠单抗联合曲妥珠单抗治疗南亚绝经后老年妇女非转移性her2阳性乳腺癌的安全性评估

IF 1.9

International Journal of Breast Cancer Pub Date : 2018-04-19 eCollection Date: 2018-01-01 DOI: 10.1155/2018/6106041

Nadia Hussain, Amira S A Said, Zainab Khan

{"title":"Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia.","authors":"Nadia Hussain, Amira S A Said, Zainab Khan","doi":"10.1155/2018/6106041","DOIUrl":"https://doi.org/10.1155/2018/6106041","url":null,"abstract":"Aim: To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20-25% of breast cancer signals an aggressive form of breast cancer and is treated with trastuzumab and pertuzumab.Methods: The patient record database was accessed to identify all postmenopausal women in the Punjab Care hospital who were above 65 years old, with stages 1-3 HER2-positive breast cancer and treated with neoadjuvant TCHP and neoadjuvant TCP from 2013 till 2016.Results: In TCH-P group and TCH group, mild fatigue (34% versus 36%) and diarrhea (48% versus 49%) were most common toxicities. Fever in TCH-P group and TCH group (12% versus 13%) was common. Anorexia affected 21% and 16% of patients receiving TCH and TCHP regimen, respectively. Febrile neutropenia was higher in TCH-P group 13% (3/23) versus 4.5% (1/22) in TCH group. Also 27.2% (6/22) of TCH-P group was hospitalized for treatment related toxicities versus 21.7% (5/23) of TCH group.Conclusion: Comparing neoadjuvant TCP and neoadjuvant TCH-P showed TCH-P regimen had an acceptable toxicity profile. Severe cardiac dysfunction was not observed. Using TCH-P regimen can be considered as relatively safe therapeutic option for elderly postmenopausal women with nonmetastatic HER2-positive breast cancer.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2018 ","pages":"6106041"},"PeriodicalIF":1.9,"publicationDate":"2018-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/6106041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36178370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Breast-i Is an Effective and Reliable Adjunct Screening Tool for Detecting Early Tumour Related Angiogenesis of Breast Cancers in Low Resource Sub-Saharan Countries. 在资源匮乏的撒哈拉以南国家，Breast- 1是一种有效可靠的辅助筛查工具，用于检测乳腺癌早期肿瘤相关血管生成。

IF 1.6

International Journal of Breast Cancer Pub Date : 2018-04-04 eCollection Date: 2018-01-01 DOI: 10.1155/2018/2539056

Frank Naku Ghartey, David Watmough, Samuel Debrah, Martin Morna, Akwasi Anyanful

{"title":"Breast-i Is an Effective and Reliable Adjunct Screening Tool for Detecting Early Tumour Related Angiogenesis of Breast Cancers in Low Resource Sub-Saharan Countries.","authors":"Frank Naku Ghartey, David Watmough, Samuel Debrah, Martin Morna, Akwasi Anyanful","doi":"10.1155/2018/2539056","DOIUrl":"10.1155/2018/2539056","url":null,"abstract":"Background: What cheaper alternative breast screening procedures are available to younger women in addition to clinical breast examination (CBE) in Sub-Saharan countries? In 2009, we first described BreastLight for screening and reported high sensitivity at detecting breast cancer. Due to limitations of BreastLight, we have since 2014 been using the more technologically advanced Breast-i to screen 2204 women to find cheaper screening alternatives.Methodology: First, the participant lies down for CBE and then, in a darkened room, Breast-i was placed underneath each breast and trained personnel confirm vein pattern and look out for dark spot(s) to ascertain the presence of suspicious angiogenic lesion(s).Results: CBE detected 153 palpable breast masses and Breast-i, which detects angiogenesis, confirmed 136. However, Breast-i detected 22 more cases of which 7 had angiogenesis but were not palpable and 15 were missed by CBE due to large breast size. Overall confirmed cases were 26, with Breast-i detecting 7 cases missed by CBE. Breast-i and CBE gave sensitivities of 92.3% and 73%, respectively.Conclusion: Breast-i with its high sensitivity to angiogenesis, reliability, and affordability will be an effective adjunct detection device that can be used effectively to increase early detection in younger women, thereby increasing treatment success.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2018 ","pages":"2539056"},"PeriodicalIF":1.6,"publicationDate":"2018-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36178369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postmastectomy Radiation Therapy: Are We Ready to Individualize Radiation? 乳房切除术后放射治疗：我们准备好个性化放疗了吗？

IF 1.9

International Journal of Breast Cancer Pub Date : 2018-03-01 eCollection Date: 2018-01-01 DOI: 10.1155/2018/1402824

Ashlyn S Everett, Drexell Hunter Boggs, Jennifer F De Los Santos

引用次数: 0

Establishing the Role of Stereotactic Ablative Body Radiotherapy in Early-Stage Breast Cancer. 确定立体定向烧蚀体放疗在早期乳腺癌中的作用。

IF 1.6

International Journal of Breast Cancer Pub Date : 2018-02-01 eCollection Date: 2018-01-01 DOI: 10.1155/2018/2734820

Aisling Barry, Anthony Fyles

引用次数: 0

Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine. 包括自体福尔马林固定肿瘤疫苗在内的骨转移性乳腺癌综合治疗后1年及以上的临床完全缓解率

IF 1.9

International Journal of Breast Cancer Pub Date : 2018-01-22 eCollection Date: 2018-01-01 DOI: 10.1155/2018/4879406

Fumito Kuranishi, Yuki Imaoka, Yuusuke Sumi, Yoji Uemae, Hiroko Yasuda-Kurihara, Takeshi Ishihara, Tsubasa Miyazaki, Tadao Ohno

{"title":"Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.","authors":"Fumito Kuranishi, Yuki Imaoka, Yuusuke Sumi, Yoji Uemae, Hiroko Yasuda-Kurihara, Takeshi Ishihara, Tsubasa Miyazaki, Tadao Ohno","doi":"10.1155/2018/4879406","DOIUrl":"https://doi.org/10.1155/2018/4879406","url":null,"abstract":"Introduction: No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV).Patients and methods: AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues.Results: Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988-2002) and in the nationwide population-based cohort study of Denmark (1999-2007).Conclusion: Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2018 ","pages":"4879406"},"PeriodicalIF":1.9,"publicationDate":"2018-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4879406","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35945968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study. 在接受预防性乳房切除术的 BRCA1/2 基因突变携带者中使用前哨淋巴结活检：回顾性连续病例系列研究。

IF 1.9

International Journal of Breast Cancer Pub Date : 2018-01-01 DOI: 10.1155/2018/1426369

Sara Câmara, Daniela Pereira, Saudade André, Beatriz Mira, Fátima Vaz, Rodrigo Oom, José Carlos Marques, João Leal de Faria, Catarina Rodrigues Dos Santos

{"title":"The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.","authors":"Sara Câmara, Daniela Pereira, Saudade André, Beatriz Mira, Fátima Vaz, Rodrigo Oom, José Carlos Marques, João Leal de Faria, Catarina Rodrigues Dos Santos","doi":"10.1155/2018/1426369","DOIUrl":"10.1155/2018/1426369","url":null,"abstract":"Introduction: Sentinel lymph node biopsy in prophylactic mastectomy is controversial. It avoids lymphadenectomy in occult carcinoma but is associated with increased morbidity. Women with BRCA mutations have a higher incidence of occult carcinoma and our objective was to assess the clinical utility of sentinel lymph node biopsy when these women undergo prophylactic mastectomy.Materials and methods: Seven-year retrospective consecutive case-series study of women, with a BRCA deleterious mutation, admitted to prophylactic mastectomy, at our center. Breast MRI < 6 months before surgery was routine, unless contraindicated.Results: Fifty-seven patients (43% BRCA1; 57% BRCA2) underwent 80 prophylactic mastectomies. 72% of patients had had breast cancer treated before prophylactic mastectomy or synchronously to it. The occult carcinoma incidence was 5%, and half of the cases were invasive. SLNB was performed in 19% of the prophylactic mastectomies; none of these had tumor invasion. Women with invasive carcinoma who had not undergone sentinel lymph node biopsy were followed closely with axillary ultrasound. The median follow-up was 37 months, with no local recurrence; 1 patient died of primary tumor systemic relapse.Conclusions: Our data do not support this procedure for routine (in agreement with previous literature), in this high risk for occult carcinoma population.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2018 ","pages":"1426369"},"PeriodicalIF":1.9,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35885507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Semaphorin 3A Increases FAK Phosphorylation at Focal Adhesions to Modulate MDA-MB-231 Cell Migration and Spreading on Different Substratum Concentrations 信号蛋白3A增加FAK在局灶黏附中的磷酸化，调节MDA-MB-231细胞在不同基质浓度下的迁移和扩散

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-15 DOI: 10.1155/2017/9619734

Scott Gehler, Frances V. Compere, A. M. Miller

{"title":"Semaphorin 3A Increases FAK Phosphorylation at Focal Adhesions to Modulate MDA-MB-231 Cell Migration and Spreading on Different Substratum Concentrations","authors":"Scott Gehler, Frances V. Compere, A. M. Miller","doi":"10.1155/2017/9619734","DOIUrl":"https://doi.org/10.1155/2017/9619734","url":null,"abstract":"Interactions between integrin-mediated adhesions and the extracellular matrix (ECM) are important regulators of cell migration and spreading. However, mechanisms by which extracellular ligands regulate cell migration and spreading in response to changes in substratum concentration are not well understood. Semaphorin 3A (Sema3A) has been shown to inhibit cell motility and alter integrin signaling in various cell types. We propose that Sema3A alters focal adhesions to modulate breast carcinoma cell migration and spreading on substrata coated with different concentrations of ECM. We demonstrate that Sema3A inhibits MDA-MB-231 cell migration and spreading on substrata coated with high concentrations of collagen and fibronectin but enhances migration and spreading at lower concentrations of collagen and fibronectin. Sema3A increases focal adhesion kinase phosphorylation at tyrosine 397 (pFAK397) at focal adhesions on all substratum concentrations of collagen and fibronectin but decreased pFAK397 levels on laminin. Rho-associated protein kinase (ROCK) inhibition blocks the Sema3A-mediated effects on cell migration, spreading, and pFAK397 at focal adhesions when cultured on all concentrations of collagen. These results suggest that Sema3A shifts the optimal level of cell-matrix adhesions to a nonoptimal ECM coating concentration, in particular collagen, to yield maximal cell migration and spreading that may be mediated through a ROCK-dependent mechanism.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"81 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2017-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89663012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients 500多例Oncotype DX复发评分与组织形态学和免疫组织化学的相关性

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-12 DOI: 10.1155/2017/1257078

M. Hanna, I. Bleiweiss, A. Nayak, S. Jaffer

{"title":"Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients","authors":"M. Hanna, I. Bleiweiss, A. Nayak, S. Jaffer","doi":"10.1155/2017/1257078","DOIUrl":"https://doi.org/10.1155/2017/1257078","url":null,"abstract":"Oncotype Dx is used to determine the recurrence risk (RR) in patients with estrogen receptor positive (ER+) and lymph node negative (LN−) breast cancer. The RR is divided into low (0–17), intermediate (18–30), and high (31) to predict chemotherapy benefit. Our goal was to determine the association between histomorphology, immunohistochemistry, and RR. We retrospectively identified 536 patients with ER+ and LN− breast cancers that underwent Oncotype testing from 2006 to 2013. Tumor size ranged from 0.2 cm to 6.5 cm (mean = 1.3 cm) and was uniform in all 3 categories. The carcinomas were as follows: ductal = 63.2%, lobular = 11.1%, and mixed = 35.7%. The RR correlated with the Nottingham grade. Increasing RR was inversely related to PR positivity but directly to Her2 positivity. Of the morphologic parameters, a tubular(lobular) morphology correlated only with low-intermediate scores and anaplastic type with intermediate-high scores. Other morphologies like micropapillary and mucinous were uniformly distributed in each category. Carcinomas with comedo intraductal carcinoma were more likely associated with high RR. Forty-four patients with either isolated tumor cells or micrometastases were evenly distributed amongst the 3 RR. While there was only 1 ER discrepancy between our immunohistochemistry (3+ 80%) and Oncotype, up to 8% of PR+ cases (mean = 15%, median = 5%) and 2% of HER2+ cases were undervalued by Oncotype.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"43 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2017-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75770205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36

Quality of Breast Cancer Information on the Internet by African Organizations: An Appraisal 非洲组织在互联网上的乳腺癌信息质量:评估

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-11 DOI: 10.1155/2017/2026979

C. P. Akuoko

{"title":"Quality of Breast Cancer Information on the Internet by African Organizations: An Appraisal","authors":"C. P. Akuoko","doi":"10.1155/2017/2026979","DOIUrl":"https://doi.org/10.1155/2017/2026979","url":null,"abstract":"Objective. The aim of this study was to appraise the quality of information on BC available at websites run by organizations in Africa. Methods. Three searches were conducted using Google search engine to generate a list of websites. The identified websites were assessed using European Commission (EC) quality criteria for health-related websites, which comprises different assessment areas including, completeness, transparency and honesty, authority, privacy and data protection, updating of information, accountability, and accessibility. Results. Thirteen (13) websites were included in the evaluation. Majority of the websites evaluated had low scores on the completeness and transparency of their websites. Scores on accessibility were however moderate and high for most of the websites. Breast cancer-specific organizations provided the highest quality information, particularly in terms of completeness. The overall lowest and highest quality scores were 9 and 43 out of 63, respectively, and 77% of the included websites scored less than 50% of the total quality score. Conclusion. This review has provided evidence of inadequate and inaccurate BC information provided by some cancer organizations in Africa. Considerable effort is required to make BC information on the Internet a valuable and up-to-date source for both professionals and patients.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"58 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2017-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85521170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3